share_log

B. Riley Securities Initiates Coverage On Nektar Therapeutics With Buy Rating, Announces Price Target of $4

Benzinga ·  Jan 8 06:37  · Ratings

B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment